Avenue Therapeutics Stock News

After a fairly robust 2021, the new year started on a mixed note as far as regulatory decisions are concerned. About three new molecular entities, or NMEs, were approved during the month, including Im

Avenue Therapeutics Inc (ATXI) shares closed 2.4% lower than its previous 52 week low, giving the company a market cap of $16M. The stock is currently down 1.4% year-to-date, down 85.6% over the past 12 months, and down 89.2% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 66.6% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -189.0% The company's stock price performance over the past 12 months lags the peer average by 13447.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Avenue Therapeutics Inc (ATXI) shares closed today at 1.7% above its 52 week low of $0.88, giving the company a market cap of $17M. The stock is currently down 1.3% year-to-date, down 85.6% over the past 12 months, and down 89.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.7%. Trading Activity Trading volume this week was 44.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.1. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 2.2% lower than its 5-day moving average, 6.6% lower than its 20-day moving average, and 33.6% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -251.9% The company's stock price performance over the past 12 months lags the peer average by 6442.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Avenue Therapeutics Inc (ATXI) shares closed today at 0.1% above its 52 week low of $0.88, giving the company a market cap of $16M. The stock is currently down 85.2% year-to-date, down 84.8% over the past 12 months, and down 89.3% over the past five years. This week, the Dow Jones Industrial Average rose 2.1%, and the S&P 500 rose 2.1%. Trading Activity Trading volume this week was 8.6% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 790.1% The company's stock price performance over the past 12 months lags the peer average by 864.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Avenue Therapeutics, Inc. (NASDAQ:ATXI) was the recipient of a large decline in short interest in the month of November. As of November 30th, there was short interest totalling 107,600 shares, a decline of 20.2% from the November 15th total of 134,800 shares. Currently, 1.2% of the companys shares are short sold. Based on an average []

NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (or the “Company”) (NASDAQ: ATXI), a company focused on the development of intravenous (“IV”) tramadol for the U.S. mark

NEW YORK, Dec. 12, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, toda

NEW YORK, Dec. 12, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $2.0 million, before deducting underwriting discounts and commissions and other estimated expenses payable by the Company. The offering equates to 1,910,100 shares at a price to the public of $1.07 per share. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes.

The stock price of Avenue Therapeutics Inc (NASDAQ: ATXI) increased by 53.15% in the most recent trading session. This is why it happened.

Shares of penny stocks PTPI & ATXI are on the move and here’s what’s going on. The post Best Penny Stocks Today: Why ATXI & PTPI Stock Are Moving appeared first on Penny Stocks to Buy, Picks, News

Avenue Therapeutics, Inc. (NASDAQ:ATXI) was the recipient of a significant growth in short interest during the month of October. As of October 29th, there was short interest totalling 270,500 shares, a growth of 21.1% from the October 14th total of 223,300 shares. Currently, 4.1% of the shares of the company are short sold. Based on []

NEW YORK, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (the “Company”) (NASDAQ: ATXI), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market,

NEW YORK, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (the Company) (NASDAQ: ATXI), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today announced that the underwriter of its previously announced underwritten public offering has exercised, in full, its option to purchase an additional 292,018 shares of common stock at a price of $1.34 per share. Total gross proceeds to the Company from the offering, including the funds received from the prior closing and exercise of this option, are approximately $3 million, before deducting underwriting discounts, commissions, and other offering expenses payable by the Company.

Novavax, Inc. (NASDAQ: NVAX), Orphazyme A/S (NASDAQ: ORPH) and Avenue Therapeutics, Inc. (NASDAQ: ATXI) are among the biggest movers among biopharma stocks Monday. Novavax Finally Releases Phase 3 COV

NEW YORK, June 14, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today